Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.
Narrow List by Age:
(Refer to Clinical Summary for age requirements)
Protocol | TAPUR |
---|---|
Cancer Type: | Multisite |
Fast Facts |
Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | 10323 Moonshot |
---|---|
Cancer Type: | Biospecimen |
Fast Facts |
Cancer Moonshot Biobank Research Protocol
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAY131 - MATCH |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH)
Protocol | SWOG S1609 DART |
---|---|
Cancer Type: | Rare Tumors |
Fast Facts |
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Protocol | EAY131 - MATCH Protocol Z1M |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG ALTE2031 |
---|---|
Cancer Type: | multisite |
Fast Facts |
ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors
Patient must be ≥15 years and < 21 years at the time of enrollment.
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | Alliance A231601CD |
---|---|
Cancer Type: | CCDR |
Fast Facts |
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | DCP-001 |
---|---|
Cancer Type: | Multisite - Screening |
Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | COG AGCT1531 |
---|---|
Cancer Type: | Germ Cell |
Fast Facts |
A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors
Age:
Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.
Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.
Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment.
Protocol | COG APEC14B1 |
---|---|
Cancer Type: | All patients |
Fast Facts |
The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.
Protocol | COG ALTE03N1 |
---|---|
Cancer Type: | Multi-site Cancer Control |
Fast Facts |
Key Adverse Events After Childhood Cancer
Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.
Protocol | COG ALTE05N1 |
---|---|
Cancer Type: | Multisite Long Term Follow-up |
Fast Facts |
Umbrella Long-Term Follow-Up Protocol
Only Available to Patients Already Enrolled on a COG Intervention Protocol.
Protocol | COG ALTE07C1 |
---|---|
Cancer Type: | Multi-Site Cancer Control |
Fast Facts |
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer
Protocol | COG APEC1621 – MATCH Protocol SC |
---|---|
Cancer Type: | Screening |
Fast Facts |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Protocol | COG APEC1621 - MATCH |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol
Protocol | COG APEC1621 - MATCH Protocol A |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol B |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol D |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol F |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 – MATCH Protocol I |
---|---|
Cancer Type: | Molecular |
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol K |
---|---|
Cancer Type: | Molecular |
APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol M |
---|---|
Cancer Type: | Molecular |
APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations
Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG APEC1621 - MATCH Protocol N |
---|---|
Cancer Type: | Molecular |
APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations
Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.
Protocol | COG ARST1921 |
---|---|
Cancer Type: | Other |
Fast Facts |
COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
Please check out the rare protocol list to locate other studies within this disease site.
Protocol | EAY131 - MATCH Protocol H |
---|---|
Cancer Type: | Molecular |
Fast Facts |
Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)
Please check out the rare protocol list to locate other studies within this disease site.
Cancer clinical trials are research studies for developing better ways of detecting,
treating, and eventually preventing cancer. By taking part in a clinical trial,
you are among the first to receive new research treatments before they are widely
available. Your participation in a clinical trial will influence the future direction
of cancer care.
If you are interested in participating in a clinical trial, consult with your physician.
Please note: clinical trials are not risk free. Patients must explore the options
that are best for their individuals needs with the help of their physician.